Abeona Therapeutics trades as part of the healthcare sector and is part of the biotechnology industry. The company CEO is Joao Siffert. Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.
Previous Intraday Performance:
The ABEO shares had a previous change of 0.92% which opened at 6.53 and closed at 6.55. It moved to an intraday high of 6.78 and a low of 6.49.
SeekingAlpha: Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q1 2019 Results – Earnings Call Transcript
Historical Performance:
Over the last five trading days, ABEO shares returned -10.76% and in the past 30 trading days it returned -14.82%. Over three months, it changed 0.00%. In one year it has changed -59.13% and within that year its
52 week high was 18.90 and its 52 week low was 6.26. ABEO stock is 4.65% above its 52 week low.
Our calculations result in a 200 day moving average of 9.08 and a 50 day moving average of 7.65. Right now, ABEO stock is trading -27.84% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q1 2019 Results – Earnings Call Transcript
Liquidity:
The company has a market cap of $322.0m with 49.2m shares outstanding and a float of 47.0m shares. Trading volume was 341,623 shares and has experienced an average volume of 417,250 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Abeona Therapeutics was -1.23 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.31.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.39 |
|---|---|---|
| 4th | Qtr 2018 | -0.42 |
| 3rd | Qtr 2018 | -0.34 |
| 2nd | Qtr 2018 | -0.25 |
| 1st | Qtr 2018 | -0.22 |
The growth of the EPS is critical in understanding the current valuation of Abeona Therapeutics; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -65.40% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 95.80% of institutional ownership.
The beta was calculated to be 2.06.
SeekingAlpha: Wall Street Breakfast: Global Markets Suffer As U.S.-China Dispute Intensifies
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -45.09%, return on assets is -37.86%, price-to-sales is 797.65 and price-to-book is 2.73.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: ABEO, Abeona Therapeutics, Biotechnology, Healthcare
